Tumor heterogeneity may reduce the efficacy of molecularly guided systemic therapy for cancers that have metastasized. To determine whether the genomic alterations in a single metastasis provide a reasonable assessment of the major oncogenic drivers of other dispersed metastases in an individual, we analyzed multiple tumors from men with disseminated prostate cancer through whole-exome sequencing, array comparative genomic hybridization (CGH) and RNA transcript profiling, and we compared the genomic diversity within and between individuals. In contrast to the substantial heterogeneity between men, there was limited diversity among metastases within an individual. The number of somatic mutations, the burden of genomic copy number alterations and aberrations in known oncogenic drivers were all highly concordant, as were metrics of androgen receptor (AR) activity and cell cycle activity. AR activity was inversely associated with cell proliferation, whereas the expression of Fanconi anemia (FA)-complex genes was correlated with elevated cell cycle progression, expression of the E2F transcription factor 1 (E2F1) and loss of retinoblastoma 1 (RB1). Men with somatic aberrations in FA-complex genes or in ATM serine/threonine kinase (ATM) exhibited significantly longer treatment-response durations to carboplatin than did men without defects in genes encoding DNA-repair proteins. Collectively, these data indicate that although exceptions exist, evaluating a single metastasis provides a reasonable assessment of the major oncogenic driver alterations that are present in disseminated tumors within an individual, and thus may be useful for selecting treatments on the basis of predicted molecular vulnerabilities. npg
Personalized approaches for cancer treatment rely on the premise that defined molecular alterations in tumors will confer susceptibility to specific therapeutics, and that malignancies without the alteration will not respond 1 . Consequently, the identification of subsets of cancer patients with or without a particular oncogenic driver is predicted to enhance treatment efficacy and reduce futile interventions. This concept requires heterogeneity between individuals with respect to the composition of therapy vulnerability characteristics, and it is supported by studies that demonstrate extensive diversity in genomic aberrations and treatment responses among cancers with the same histological classification 2-8 . To achieve full success, precision oncology also requires limited molecular heterogeneity within an individual, such that the targeted vulnerability is represented in most or all tumor cells.
Although striking successes have been achieved with therapies that exploit vital drivers of tumor cell growth 9 , deep molecular profiling has uncovered a substantial degree of intratumoral heterogeneity and the existence of divergent cancer clones within a primary tumor [10] [11] [12] . The extent of this diversity indicates the potential for misclassification when using current biopsy-based strategies that may under-sample tumors, and it provides clear pathways to rapid treatment resistance. To date, most studies that assess the extent of tumor heterogeneity have characterized primary tumors. However, localized carcinomas are generally managed with surgery or radiation, which are often curative. A major unmet need involves the systemic treatment of metastatic cancer, which usually involves multiple spatially distributed anatomic sites. There is limited information concerning the molecular diversity of the metastatic burden within an individual [13] [14] [15] . Such knowledge has considerable implications for the success of precision oncology.
Here we analyzed the intraindividual molecular diversity of metastatic prostate cancer (mPC), a disease that accounts for more than 27,000 deaths annually in the US 16 . The mainstay of initial therapy for mPC, which has remained essentially unchanged for more than 50 years, relies on the suppression of circulating levels of testosterone, and consequently, suppression of the AR signaling program in PC cells 17 . This therapy, which was conceptually one of the first precisionmedicine approaches to cancer treatment, is highly effective: response rates exceed 90%, and durations of disease control last approximately 24 months. At the time of disease progression-a nearly universal event-metastatic castration-resistant prostate cancers (mCRPC) exhibit a spectrum of recurrent molecular aberrations, some of which are predicted to confer susceptibility to targeted therapeutics [18] [19] [20] [21] .
Our objective was to determine whether the molecular composition of a single metastatic focus at a particular point in the treatment continuum provides a reasonable assessment of the major oncogenic drivers of the other dispersed metastases in an individual. We used whole-exome sequencing (WES), array CGH and transcript profiling to characterize the composition of metastatic tumors, and we evaluated the consistency and diversity of molecular aberrations within and between individuals.
RESULTS

Genomic landscapes of metastatic prostate cancers
We resected 176 primary or metastatic tumors from 63 men with mCPRC at the time of rapid autopsy, and determined mutations by WES (n = 141 tumors from 56 men), copy number alterations by 40 KLK2  KLK3  NKX3-1  PMEPA1  ELL2  GNMT  ABCC4  ACSL3  CENPN  C1orf116  TMPRSS2  FKBP5  HERC3  PTGER4  ADAM7  EAF2  ZBTB10 NNMT 26 and Grasso et al. 19 studies of untreated primary PC and mCRPC. (c) AR activity as determined by transcript levels of 21 AR-regulated genes across CRPC tumors obtained at rapid autopsy. AR activity scores are also shown for microdissected cell populations of bladder urothelium (bladder); BP, benign prostate epithelium; CP, primary prostate cancer; G, Gleason pattern. AR somatic mutation and CN status for each tumor sample are shown in the lower matrix. (d) Consistency of the AR activity score for metastatic tumors within individuals, and diversity of the AR activity score in tumors between individuals. The y axis is the AR activity score and x axis shows individual men. Scores for individual tumors are plotted over a range of 0-100% as a box and whiskers plot, with the box showing the interquartile range (IQR) and the upper and lower whiskers extending to the values that are within 1.5 × IQR; data beyond the end of the whiskers are outliers and plotted as points. Colors are used to denote different individuals. Circles are metastatic tumors (n = 149) and triangles are primary tumors (n = 22) resected at rapid autopsy.
npg array CGH (n = 149 tumors from 60 men) and transcript expression by microarray hybridization (n = 171 tumors from 63 men). A small subset of tumors could not be evaluated by all three methods because of limited tumor quantity. Histological assessments of each metastasis determined that the vast majority (n = 156) were adenocarcinomas, and that 20 tumors from two men were of small-cell neuroendocrine histology. All men were treated with androgen-deprivation therapy (ADT), and after disease progression, most of them also received additional treatments, including at least one additional AR pathwaytargeted agent and at least one systemic chemotherapy, most commonly docetaxel ( Supplementary Tables 1 and 2) . We found recurrent aberrations involving genes previously reported to be altered in mCRPC, including AR, ERG, TP53, RB1, SPOP, CHD1, and ZBTB16, as well as gain in regions of chromosome 8q (including the MYC locus) and loss in regions of 8p ( Fig. 1a) . We also identified recurrent mutations in the FOXA2 gene, which encodes a transcription factor expressed in tumors that exhibit neuroendocrine features ( Supplementary Fig. 1a,b) 22, 23 . Metastases from five men exhibited hypermutated genomes with complex structural aberrations in the MSH2 and MSH6 mismatch-repair genes 24 . All metastases and primary tumors from these men were hypermutated, which suggests that mismatch-repair deficiency occurred early in the genesis of these carcinomas.
Overall, the molecular landscapes of the lethal PCs exhibited a subset of aberrations that were observed recurrently across men, as well as combinations of events that were unique to tumors originating within an individual. When men with hypermutated tumors were excluded, the number of protein-coding mutations averaged 44 events per tumor, and the overall percentage of tumor genomes affected by structural changes (the CNA burden 25 ) averaged 38%, although there were wide ranges in these metrics. Notably, most tumors from any given man exhibited similar numbers of mutations and a similar CNA burden, and there were no differences in overall mutation abundance, or in aberrations in any specific genes associated with specific visceral or bone metastatic sites ( Supplementary Fig. 1c-g) .
AR activity is maintained in the majority of CRPC metastases Amplification or mutation of the AR gene occurred in 63% of men ( Fig. 1a) . Such aberrations were extremely rare in untreated primary PCs (Fisher's exact test; P < 0.0001) ( Fig. 1b) . By using a geneexpression signature of AR transcriptional output 26 , we found that 88% of men had tumors with robust AR activity, despite extensive prior treatment to suppress AR function ( Fig. 1c) . To evaluate this more fully, we assessed AR expression and AR output across multiple metastases from individual men. AR activity scores ( Fig. 1d ) and AR expression ( Supplementary Fig. 2a ) diverged across individuals, but they were highly concordant among metastases within individuals. AR expression was positively associated with the amplification of the AR locus (P ≤ 0.05), but it did not differ among lymph node, visceral or bone metastatic sites (Supplementary Fig. 2b,c) . AR genomic aberrations were generally concordant within individuals: in eight men, all tumors were consistent in having no AR aberrations, and for 24 men, all tumors were found to have either AR copy gain or mutation. In nine men, there was discordance, with one or more tumors exhibiting an AR copy gain or mutation and one or more tumors showing no aberration. We identified one man with evidence of convergent evolution, in whom several metastases had AR mutation and other metastases had AR amplification, each potentially a contributor to treatment resistance. In two men with small-cell carcinomas confirmed by histology and immunohistochemical stains showing chromogranin expression, high neuroendocrine (NE) and low AR activity signatures were concordant across all metastases ( Supplementary Fig. 2d ).
Although AR expression was usually associated with AR activity, we identified outliers that showed high AR activity but absent or limited expression of the AR gene itself ( Fig. 2a) . Previous reports indicate that other nuclear hormone receptor genes, such as the glucocorticoid receptor (nuclear receptor subfamily 3 group C member 1 gene, NR3C1, also known as GR), the progesterone receptor (PGR) or the estrogen receptor (ESR1), could activate canonical AR target genes [27] [28] [29] [30] . In a minority of tumors, NR3C1and ESR1 were expressed in the absence of AR (Fig. 2b,c) , and thus could account for the maintenance of at least a component of the AR transcriptome. Limited genomic diversity within patients The substantial concordance of AR-or NE-associated gene expression across metastases within an individual prompted a further assessment of intraindividual molecular diversity. Presumptive driver aberrations identified in a representative tumor from each man were generally shared by all tumors in that individual. For example, patient 99-091 had AR copy gain, high AR activity, mutation in tumor protein p53 (TP53) and lacked an v-ets avian erythroblastosis virus E26 oncogene homolog (ERG) rearrangement (Fig. 3a) . The other four evaluable tumors from 99-091 shared these and other features. CNAs were also highly concordant ( Fig. 3a) . At the mutation level, a subset of nonsynonymous single nucleotide variants (NSVs) were shared, although each tumor had private mutations, of which few were predicted to be deleterious (Fig. 3b) . To further assess the potential for these metastasis-private NSVs to influence pathogenesis, we examined WES data from 333 primary PCs from The Cancer Genome Atlas (TCGA) 31 and 150 mCRPC tumors from the Stand Up to Cancer and Prostate Cancer Foundation (SU2C-PCF) study 20 . Of 51 genes with NSVs exclusive to an individual metastasis from patient 99-091, only two, CUB and Sushi multiple domains 1 (CSMD1) and nuclear CCP activity receptor corepressor 2 (NCOR2), were altered at frequencies that exceeded 5% in either the TCGA or the SU2C-PCF tumors. Similar results were observed across multiple tumors from other men ( Supplementary  Figs. 3 and 4) . Collectively, these data suggest that most mutations unique to an individual tumor are not drivers of tumor behavior. By using an integrated analysis that incorporated CNAs, mutations and gene expression, we found that all tumors from a given individual congregated closely with other tumors from the same individual, and that they were distinct from tumors in other men ( Fig. 3c and  Supplementary Figs. 3 and 4) . Unsupervised clustering based on CNA profiles grouped tumors from the same individual together with nearly 100% accuracy ( Fig. 3d) . Of note, when the primary tumor removed at the time of rapid autopsy was analyzed, it grouped with the metastatic tumors from the same individual, rather than with primary tumors from different men.
We next evaluated the intraindividual consistency of a recurrent driver aberration, the TMPRSS2-ERG gene fusion, which is present in approximately 40% of primary PCs 32 . Fluorescence in situ hybridization (FISH) using TMPRSS2 and ERG probes on 53 tumors from 13 men found 100% concordance, all positive or all negative, between all metastases within an individual ( Supplementary Table 3 ). By using array CGH to identify chromosomal loss between the TMRPSS2 and ERG genes, we found that 32 of 34 men, including the 13 men with FISH results, had 100% concordance across all metastases (94%), with divergence in two men. For one individual, 00-029, FISH demonstrated that all tumors were positive for a TMPRSS2-ERG rearrangement.
Clustering tumors based on expression profiles also grouped tumors by person of origin, excepting bone metastasis (Supplementary Fig. 5a ). This may reflect inherent tumor biology, microenvironment effects, the overall lower tumor cell content of bone metastasis or technical factors that are associated with processing for transcript quantitation. Although we and others have reported differences in the expression of specific genes between bone and visceral sites 33 , we did not identify mutations or CNAs associated with metastasis location.
We next determined the overall molecular similarity and diversity of tumors by using a statistical framework. We focused on a subset of 38 men from whom multiple tumors per individual were successfully sequenced. Of the 123 tumors from this cohort, 5,389 genes harbored a somatic NSV, of which 2,843 were from hypermutated tumors, leaving 2,546 NSVs derived from 34 men and a total of 112 tumors. Collectively, there were 984 regions with defined CNAs in these tumors. We compared the NSVs and CNAs in each tumor with every other tumor, and we determined that the median percent of corresponding aberrations that differed between tumors from the same individual was 6.7%, compared to 22.1% from different individuals. The median interindividual versus intraindividual tumor difference in aberrations was 15.7% (95% CI 15.5-15.9%; P < 0.001; two-sided two-sample Wilcoxon rank-sum test). Heat maps with complete linkage dendrograms using CNAs (Fig. 3e) or mutations (Supplementary Fig. 5b ) clustered tumors according to the person of origin.
Cell cycle progression inversely correlates with AR activity
The concordance of AR activity or NE activity in tumors derived from the same person prompted further analyses to determine whether a relationship existed between these programs, as well as a key metric of treatment resistance: tumor cell proliferation. We evaluated a 31-gene signature of cell cycle progression (CCP) that was shown to be associated with PC mortality when assessed in primary tumors 34 . A wide-range of CCP activity was evident across the CRPC tumors ( Fig. 4a) . We confirmed that CCP activity was associated with cell proliferation, as determined by Ki67 immunohistochemistry on the same tumor samples (r = 0.48; P < 0.005)( Fig. 4b  and Supplementary Fig. 5c ). CCP activity was more concordant among tumors in an individual than tumors between different individuals (Fig. 4c) . There were modest positive associations between CCP activity and mutation burden (r = 0.21; P = 0.023) ( Supplementary Fig. 5d,e ).
Contrary to our expectations, AR activity was inversely associated with CCP activity (r = −0.33; P < 0.001) (Fig. 5a) , a finding confirmed in an independent data set comprising mCRPC tumors (Fig. 5b) 19 . AR activity was also inversely associated with E2F1 expression, a key regulator of cell proliferation (P < 0.001) (Fig. 5c) . To determine the functional relevance of this correlation, we compared the proliferation of wild-type (WT) cells of the androgen-responsive prostatecancer cell line LNCaP, expressing endogenous AR (LNCaP WT ), to that of LNCaP cells engineered to overexpress AR (LNCaP AR ). Proliferation of LNCaP AR cells was significantly greater than that of LNCaP WT cells at very low AR ligand concentrations of 10 −11 M of genome-wide correlations of CCP score to each gene, and found that elevated expression of FA-complex components, including FANCA, FANCI, FANCD2, BRCA1 and BRCA2, were associated with tumors that exhibit high CCP activity (Fig. 6a) . Genes comprising the FA pathway were expressed at low levels in untreated primary PCs, which also
Individual CRPC tumors the AR agonist metribolone (hereafter known as R1881) (P < 0.0001; Fig. 5d ) that approximate castrate serum testosterone concentrations achieved with ADT 35 . However, at higher ligand levels (10 −9 M), approximating concentrations in a noncastrated male, the growth of LNCaP WT cells substantially exceeded that of LNCaP AR cells, whose proliferation was suppressed by the higher androgen concentration (Fig. 5d) . After the introduction of AR into AR-null human prostate cancer PC3 cells, 10 −9 M R1881 also significantly inhibited their growth (P = 0.02) (Supplementary Fig. 5f) . These findings support the concept that in addition to oncogenic roles, the AR may have activities that suppress aspects of tumor progression 36, 37 .
CCP correlates with FA gene expression
We next sought to identify genes with expression levels that are positively associated with elevated cell proliferation. We computed npg had low CCP scores (Fig. 6a) . For several FA genes we found significant relationships between copy number and transcript levels, including FANCA (P < 0.006), BRCA1 (P < 0.005) and PALB2 (P < 0.005), although most tumors did not have alterations in genes encoding FA components (Supplementary Fig. 6a-c) . A subset of FA genes is positively regulated by E2F transcription factors, primarily by E2F1 (refs. 38,39) . We found a significant relationship between high CCP activity and loss of the RB1 tumor-suppressor locus (P < 0.01) (Fig. 6b) , which was also associated with E2F1 expression and which remained significant after removing the highly proliferative NE metastases 40 . Tumors with high E2F1 expression also had elevated CCP scores (r = 0.8; P < 0.001) and elevated activity of a signature comprising 15 FA-pathway genes (r = 0.78; P < 0.001) (Supplementary Fig. 6d-g) .
To determine whether FA components can influence cell proliferation, we suppressed the expression of individual FA genes by using short interfering RNAs (siRNAs) in the LNCaP, 22Rv1, VCaP and PC3 human PC cell lines. Suppression of each FA gene reduced the proliferation of each respective cell line (Fig. 6c,d and Supplementary  Fig. 6h,i) . Consistently with the known role of the FA complex in facilitating DNA repair, the suppression of individual FA-complex genes significantly increased the phosphorylation of H2AX (γ-H2AX), a marker of DNA double-strand breaks, in LNCaP cells after exposure to the genotoxic drug carboplatin (P < 0.05 for all FA genes tested, excepting SLX4) ( Fig. 6e) . Of the men in this rapid autopsy cohort, 20 received carboplatin chemotherapy during their clinical course. Those with a somatic aberration in a DNA repairpathway gene-defined as a homozygous deleterious event in any FApathway component or a heterozygous inactivating event in the ATM gene, events both recently shown to be associated with responses to the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib 41 -had significantly greater durations of response to carboplatin chemotherapy, as determined by time on drug treatment (P = 0.02) (Fig. 6f) .
DISCUSSION
Comprehensive molecular assessments of PC have identified numerous recurrent genomic and epigenomic aberrations in genes that are implicated in driving cancer development, of which a substantial fraction have clinical implications for directing treatment 12, 19, 20, [42] [43] [44] [45] . These findings provide a rationale for tumor sequencing to identify the facets of tumor biology that prioritize and individualize therapeutics. However, deep sequencing of tumor genomes has also identified mutational heterogeneity, particularly within primary tumors. Branching evolution and the co-existence of multiple cancer lineages occur in a spectrum of carcinomas and have implications with respect to accurately sampling tumors and also for evolutionary mechanisms that may rapidly promote treatment resistance 11, 12, 46 .
In the present study of mCRPC, we determined that constellations of genomic events were unique to the individual from which a tumor was derived, which demonstrates substantial interindividual heterogeneity. In contrast, the molecular aberrations identified in multiple, spatially distinct metastases derived from a single individual and sampled at a single point in time were highly concordant, although a limited number of unique events specific to any particular tumor was evident, and very few represented known oncogenic drivers. We found that overall mutation burden, CNA burden, AR activity signature and cell cycle output were all generally concordant across tumors within an individual. Our results provide further evidence for monoclonal seeding of metastatic sites, although our methods precluded assessments of their polyclonal composition or intermixing of metastases, as has been reported by others 15 . It is important to recognize that the ability of tumor clones from one site to seed other metastatic foci and to intermix would result in a degree of homogenization, leading to the practical consequence that sampling one site has the potential to interrogate the extent of mutational heterogeneity present within an individual. Further studies are required to ascertain the influence of intratumoral heterogeneity with respect to treatment responses of tumors with variable frequencies of clones that possess druggable alterations.
Although the analysis of a single metastatic tumor site clearly does underestimate the total burden of molecular aberrations found in the totality of all metastases, most drivers and actionable features are either represented as common roots across all tumors or result from convergent evolution conferred by therapeutic pressure 15 , and most molecular differences between metastases do not seem to influence tumor phenotypes. Although there are exceptions, these findings suggest that clinical decision-making on the basis of a biopsy from a single metastatic site is reasonable. This assumption may not be relevant when sampling a primary tumor, in which greater molecular diversity seems to occur than in metastases 12 , and it must be tempered given that only three men in our study were treated with the potent AR-pathway antagonists abiraterone or enzalutamide. These antagonists could induce diverse resistance mechanisms, including AR amplification, AR mutation and expression of AR splice variants that may differ across metastases within an individual. In some situations, simply determining the activity status of a particular pathway will be sufficient for directing therapy, whereas in other instances, the mechanism by which the pathway is activated-for example, a specific AR ligand binding site mutation-will have treatment implications.
Our findings are supported by previous studies reporting substantially greater similarities in the genomic and epigenomic compositions of metastases, relative to the more expansive diversity that is found within regions of primary tumors [10] [11] [12] [45] [46] [47] [48] [49] . In addition to the severe bottlenecks imposed by the metastatic process, the time scales involved in the evolutionary stages of cellular transformation to invasion and metastasis may underlie the disparity in molecular heterogeneity within primary tumors and between metastases. It has been estimated that decades of chronological time are required for cells with initiating events to acquire sufficient additional mutations to endow subclones with the characteristics that enable invasion and metastatic spread 10 . By contrast, the intervals between the acquisition of metastatic capability and the ability to grow in distant organs generally range from only months to a few years 10 . Indeed, prostatic intraepithelial neoplasia and primary PCs are readily evident in men aged 30-40 years, decades before metastatic PC is commonly diagnosed 50 . These years of intraorgan tumor growth allow for substantial evolutionary diversity, clonal expansion, clonal mixing and the genesis of completely independent primary tumors.
In the present study, another bottleneck limiting tumor diversity may be treatment pressures that probably eliminate sensitive tumor clones and thus enable the expansion of resistant clones. Extreme diversity among metastases would probably result in the rapid expansion of one or a few metastases and the regression or stasis of others. Our finding that most metastatic sites within a given individual exhibited concordant proliferation rates suggests that there are limited differences across metastases with respect to treatment responses to ADT or taxane chemotherapy. This finding may reflect the fact that most successful therapies for mPC are directed toward AR, which functions as a core lineage oncogene 51 , or toward fundamental cellular processes, such as microtubule dynamics 6 , that are involved in cell division. In this context, the observation that FA-pathway activity is associated with a subset of tumors with high proliferation rates, which probably reflects npg important roles in replication stress 52 , coupled with the high frequency of somatic events involving DNA-repair proteins, supports a therapeutic approach that targets this pathway in selected individuals 41 .
METHODS
Methods and any associated references are available in the online version of the paper.
ONLINE METHODS
Patient enrollment and tissue acquisition. All procedures involving human subjects were approved by the Institutional Review Board (IRB) of the University of Washington and of the Fred Hutchinson Cancer Research Center. Samples were obtained from patients who died of mCRPC and who signed written informed consent for a rapid autopsy performed within 6 h of death, under the aegis of the Prostate Cancer Donor Program at the University of Washington 53 . The inclusion criteria for the Prostate Cancer Donor Program included a diagnosis of prostate cancer, informed consent to perform an autopsy and informed consent to use biospecimens for biomedical research. Visceral metastases were identified at a gross level. Biopsies of all bone sites, except ribs (a Dyke cutter was used for rib biopsies) were obtained using a drill with an attached trephine (11 mm diameter coring drill bit). All specimens were either flash frozen and embedded in Optimal Cutting Temperature compound (OCT; Tissue-Tek) or formalin-fixed and embedded in paraffin, respectively (bone metastases were decalcified in 10% formic acid before paraffin embedding). This study included 176 localized and metastatic tumors from 63 men with CRPC and a matched benign tissue sample from each individual to facilitate the identification of somatic mutations. For the molecular studies, the investigators were blinded to sample identities, and samples were randomly assigned to whole-exome sequencing runs and microarray CGH analyses. Samples were included for the molecular studies if histological analysis estimated the presence of >50% neoplastic cells, DNA quantity to be ≥3 µg and the presence of high molecular weight DNA, as determined by gel electrophoresis.
Transcript profiling. A total of 176 tumors from 63 patients were collected for profiling by expression microarray. For five tumors, RNA was of insufficient RNA quality or quantity, leaving 171 tumors from 63 patients that were successfully profiled. A Leica CM3050S cryostat was used to cut 8 µm sections, which were collected on PEN Membrane Frame Slides (Life Technologies) and immediately fixed in 95% ethanol. Sections were briefly stained (5-10 s) with hematoxylin solution according to Mayer (Sigma-Aldrich), and then dehydrated in 100% ethanol. Laser-capture microdissection (LCM) was performed with an Arcturus Veritas instrument, using both UV cutting and infrared capture lasers, with CapSure Macro LCM Caps (Life Technologies), collecting 5,000-10,000 tumor cells per sample. Digital photographs were taken of tissue sections before, during and after LCM and assessed by a pathologist to confirm the tumor content. After LCM, captured cells were lysed in Arcturus RNA Extraction Buffer. RNA was isolated using the Arcturus PicoPure RNA Isolation Kit, and DNase was treated using the Qiagen RNase-Free DNase Set. The bone metastases were sampled using a 1 mm diameter tissue punch of the frozen OCT-embedded tumors in a −20 °C cryostat. The sample was obtained from the region of the block in which there was tumor, based on a section of an adjacent decalcified formalin-fixed, paraffin-embedded (FFPE) block. RNA was isolated from the tissue cores using the RNeasy Plus Micro Kit (Qiagen, Inc.). Subsequently, total RNA from all tumors was amplified for two rounds by using the Ambion MessageAmp aRNA Kit. Probe labeling and hybridization to Agilent 44K whole human genome expression oligonucleotide microarray slides (Agilent Technologies, Inc., Santa Clara, California) was performed in accordance with the manufacturer's suggested protocols. Fluorescent array images were collected using the Agilent DNA microarray scanner G2565BA. Agilent Feature Extraction software (Agilent Technologies) was used to grid and extract the data. Data was loess-normalized within arrays (normexp background correction with offset 50) and quantile-normalized between arrays in R, using the Limma Bioconductor package by batch. Control probes were removed, duplicate probes were averaged and spots were flagged by Agilent Feature Extraction software as being foreground feature nonuniformit, and population outliers were assigned a value of 'NA' . An additional normalization step was applied to remove systematic batch effects resulting from the date of RNA-amplification by application of the ComBat function within the sva Bioconductor package to the log 2 Cy3 signal intensities. Expression microarray data are deposited in the Gene Expression Omnibus database under the accession number GSE77930.
Copy number profiling.
A total of 176 tumors from 63 patients were collected for profiling by microarray CGH. For 27 tumors, DNA was of insufficient quality or quantity, which left 149 tumors from 60 patients successfully profiled. Genomic DNA was isolated from OCT sections of localized and metastatic tissues with ≥50% tumor content, 1 mm punches from frozen bone metastases, as well as patient-matched normal tissues, using the Qiagen QiaAmp DNA Micro kit that incorporated RNase treatment. DNA quality was assessed by agarose gel electrophoresis. 1 µg of high molecular weight genomic DNA from each sample was labeled by random priming using the Agilent Genomic DNA Enzymatic Labeling Kit (Cy3-dUTP). A pool of reference normal DNA (Promega) was labeled with Cy5-dUTP. Cy3 and Cy5 probes were combined and hybridized to Agilent 2 × 400K SurePrint G3 CGH microarrays and washed following the manufacturer's specifications. Fluorescent array images were collected using the Agilent DNA microarray scanner G2505C and Agilent Feature Extraction software. Control probes were removed, duplicate probes were averaged and log 2 ratios were defined as gProcessedSignal/rProcessedSignal. Recurrent germline CNVs were identified across benign tissues uninvolved with cancer obtained from 56 patients from whom DNA of sufficient quality and quantity was obtained for this study, as well as the Grasso et al. 19 copy number data set of 28 benign samples, and a list of CNV regions defined by the Broad Institute. CGH probes mapping to sequences within these regions were removed from further analysis. The log 2 ratios were corrected for the GC content wave effect using 1 Mb windows for genome GC content. Outliers were smoothed, and the normalized log 2 ratios were segmented using the Circular Binary Segmentation (CBS) algorithm implemented with the DNAcopy Bioconductor package using default parameters and undo.splits = 'sdundo' (undo.sd = 1). The mode of the histogram of segment means was set to zero. To determine significantly recurrent regions of SCNA, the GISTIC 2.0 version 6.2 GenePattern module was applied to the segmented data using amplifications and deletions thresholds of 0.2, join.segment.size of four probes, a copy-ratio cap of 2.5, arm-level peel-off enabled, broad length cutoff of 0.7 chromosome arms and a confidence level of 95%. CGH array data are deposited in the Gene Expression Omnibus database under the accession number GSE77930.
Clustering. Unsupervised clustering of expression and CN profiles was performed in R on the 5000 most variable genes for each data set by using Pearson's correlation coefficient as the distance metric and average-linkage hierarchical clustering. Clusters were visualized using the ape R package (CRAN, The Comprehensive R Archive Network, https://cran.r-project.org/) Circular plots of expression and CN profiles by chromosome location were created with the OmicCircos R package version 1.8.0 (Bioconductor, http://bioconductor.org/) Statistical analyses. Pearson's correlation coefficient was used to study the relationships between variables shown in scatterplots by using the cor.test function in R. RB1 inactivation status was determined to be homozygous if there was a two-copy loss or one-copy loss accompanied by mutation. Single-copy loss or mutation only was categorized as heterozygous loss. The CCP activity in each of these groups was compared to the RB1 WT group using both pairwise t tests and pairwise Wilcoxon rank-sum tests, using the pairwise.t.test and pairwise. wilcox.test functions in R. The pairwise t test and pairwise Wilcoxon rank-sum test were also used to compare the number of nonsynonymous mutations and the percentage of genome altered in different metastatic tissue sites, and all copy number versus expression comparisons. Assessments of the proportions of bone or soft-tissue metastases with either homozygous phosphatase and tensin homolog (PTEN) CN loss or high gain of AR were performed by Fisher's exact test using GraphPad Prism version 6.02 (GraphPad Software, La Jolla, California). Duration on carboplatin treatment was compared for percentages of patients harboring a DNA-repair defect with those who did not by Kaplan-Meier plot with log-rank test using GraphPad Prism version 6.02. Patients with a DNA-repair defect were defined as those with any combination of the following criteria: homozygous or heterozygous loss in ATM by copy-number loss and/or mutation; homozygous loss of one of the following 15 FA-complex-associated genes (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI,  BRIP1, FANCL, FANCM, PALB2, SLX4, BRCA1) ; or germline mutation in BRCA2 and/or ATM. Exome sequencing. A total of 176 tumors from 63 patients were collected for whole-exome sequencing. For 35 tumors, DNA was of insufficient quality or npg quantity, leaving 141 tumors from 56 patients that were successfully sequenced by using the Nimblegen V2 or V3 platforms (Nimblegen, Inc.) as previously described 18 , with the following modification: in a subset of tumors, individually barcoded libraries were pooled in pairs before capture ( Supplementary  Table 2 ). Genomic DNA was isolated as described above. Sequencing was performed using the Illumina Hiseq 2000 with either 50 bp or 100 bp pairedend sequences. Reads were mapped to the human reference genome sequence (hg19) with bwa v0.7.1 (ref. 54). After the removal of PCR duplicate pairs, we performed local realignment around indels using the Genome Analysis Toolkit (GATK) 47 . We subsequently called mutations using the MuTect software package (Broad Institute, https://www.broadinstitute.org) with the following parameters: '-minimum_normal_allele_fraction 0.02-max_alt_alleles_in_normal_count 12-intervals poscont.list-fraction_contamination 0.02' and called small insertions and deletions using GATK-2.3.5 SomaticIndelDetector (Broad Institute, https://www.broadinstitute.org). The minimum phred-scaled base quality at a position to count a read was 15. A subset of paired libraries displayed a low level of cross-contamination because of barcode cross-talk. To remove common polymorphisms and to enrich for probable somatic mutations, we imposed a number of additional requirements across all samples, including requiring variants to be observed in at least 10% of reads at a position in tumor samples, requiring mutant reads to be greater than 10% of the number of mutant reads in the paired library, and removing variants present within a modified database of single-nucleotide polymorphisms (SNPs) (dbSNP v137) and matched controls that had first been stripped of all COSMIC variants. We investigated mutations for significance with MutSigCV (Broad Institute, https://www.broadinstitute. org) and using standard parameters, and we manually inspected mutations in the top 50 significant genes using the Integrative Genomics Viewer (IGV) (Broad Institute, https://www.broadinstitute.org) to remove sequence artifacts. A file of the mutations identified through whole-exome sequencing is provided in Supplementary Table 4 .
Immunohistochemistry 155 metastatic PCa tissues (including 73 soft-tissue metastases and 82 bone metastases) from a total of 50 autopsy patients (up to four sites per patient) were embedded in paraffin. A human tissue microarray (TMA) was constructed with duplicate 1 mm cores using the aforementioned tissues. Because of insufficient tissue, not all tumors subjected to molecular profiling were included on the TMA. FFPE TMA sections (5 µm) were deparaffinized and rehydrated with three changes of xylene and graded ethanol. Antigen retrieval was performed with 10 mM citrate buffer (pH 6.0) in a highpressure cooker for 30 min. Endogenous peroxidase and avidin/biotin were blocked respectively (Vector Laboratories, Inc.). Sections were then blocked with 5% normal goat-horse-chicken serum at room temperature for 1 h, and incubated with primary antibody at 4 °C overnight. After washing three times with 1 × phosphate buffered saline (PBS), slides were incubated with biotinylated secondary antibody (Vector Laboratories, Inc.), followed by ABC reagent (Vector Laboratories, Inc.) and stable DAB (Invitrogen Corp.). All sections were lightly counterstained with hematoxylin and mounted with Cytoseal XYL (Richard Allan Scientific). Mouse or rabbit IgG were used as appropriate for negative controls. Antibodies sources and dilutions: ER-β was from Biogenex cat#PU385-UP (1:100); ER-α was from Abcam, cat#ab173467 (1:500); NR3C1 was from Santa Cruz, cat#sc-8992 (1:75); AR was from Biogenex, cat#F39.4.1 (1:60); chromogranin A was from Dako, cat# DAK-A3 (1:100); and K i -67 was from Dako, cat# M7240 (1:100).
Assessments of inter-and intraindividual tumor molecular heterogeneity
Mutation and CNAs for 141 tumor samples from 56 patients whose samples had undergone successful sequencing and CGH analyses were initially examined separately. We identified 5,389 mutations across tumor samples. On the basis of visualization of individual profiles, we flagged five patients' tumors as hypermutated; these patients together contributed 2,843 (53%) unique mutations. To summarize heterogeneity across samples from nonhypermutated tumors, we excluded patients who provided these, and all mutations that were present only for these patients. This left 2,546 mutations from 129 tumor samples from 51 patients. Next, we identified 984 regions with defined chromosome copy gain or loss across tumor samples from all 56 patients. We collapsed copy numbers with one or two gains into a single category (and similarly for one or two losses).
